Share Price and Basic Stock Data
Last Updated: February 7, 2026, 2:44 pm
| PEG Ratio | 0.69 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Adeshwar Meditex Ltd operates within the medical equipment and accessories sector, reporting a market capitalization of ₹30.3 Cr and a current share price of ₹21.0. The company has demonstrated a mixed revenue trend over recent quarters. For instance, total sales reached ₹36.53 Cr in September 2020, followed by fluctuations leading to a peak of ₹46.26 Cr in September 2023. However, sales decreased to ₹33.59 Cr in March 2024 before recovering to ₹40.90 Cr in September 2024. Over the past fiscal year, Adeshwar recorded annual sales of ₹82.36 Cr, a notable increase from ₹64.76 Cr in the previous year. The trailing twelve months (TTM) sales stood at ₹67.51 Cr, indicating a consistent revenue generation capacity. The company’s operational efficiency is reflected in its reported operating profit margin (OPM) of 5.12%, slightly below industry averages but consistent with its historical performance.
Profitability and Efficiency Metrics
Adeshwar Meditex has exhibited variable profitability metrics over the years. The net profit for the fiscal year 2023 was ₹2.07 Cr, maintaining the same figure in fiscal year 2025. The return on equity (ROE) stood at 5.51%, indicating a modest return for shareholders. The company reported an interest coverage ratio (ICR) of 3.47x, demonstrating its ability to meet interest obligations comfortably. However, the operating profit margin (OPM) has fluctuated, with a peak of 10.12% in March 2021, declining to 5.12% in the latest reporting period. The cash conversion cycle (CCC) was recorded at 175.13 days, reflecting the time taken to convert investments in inventory and other resources into cash flows from sales. These profitability metrics suggest that while Adeshwar is capable of generating profits, its margins warrant further scrutiny to align more closely with industry standards.
Balance Sheet Strength and Financial Ratios
As of September 2025, Adeshwar Meditex reported total assets of ₹62.70 Cr, with total liabilities amounting to ₹62.70 Cr as well. The company’s reserves have grown to ₹23.26 Cr, while borrowings have significantly reduced to ₹6.10 Cr, indicating improved financial health. The debt-to-equity ratio stood at 0.33, showcasing a low reliance on debt financing compared to equity. The current ratio of 2.03 suggests strong liquidity, indicating the company can cover its short-term liabilities comfortably. However, with a price-to-book value (P/BV) of 0.65x, the market currently values the company below its book value, which may signal undervaluation or investor skepticism regarding future growth prospects. Additionally, the return on capital employed (ROCE) is at 8.27%, which, while decent, is below the optimal range seen in the healthcare sector.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Adeshwar Meditex demonstrates a significant presence of promoters, holding 57.55% as of September 2025, which reflects strong insider confidence in the company’s future. The public holds 42.44% of the shares, while there is no reported foreign institutional investment (FII) or domestic institutional investment (DII). The number of shareholders has remained relatively stable, with 187 shareholders recorded in the latest filings. This stability in ownership suggests a loyal investor base, but the absence of institutional investment could indicate a lack of broader market confidence or awareness. The fluctuating shareholding of promoters over recent quarters, which varied from 42.65% in September 2021 to the current high, suggests a strategic repositioning that may impact investor sentiment positively.
Outlook, Risks, and Final Insight
Adeshwar Meditex’s outlook appears cautiously optimistic, given its recent revenue recovery and improved balance sheet metrics. However, several risks persist, including fluctuating profit margins and the company’s reliance on a relatively small shareholder base without institutional backing. The ongoing fluctuations in sales and operating profits may hinder long-term growth unless addressed. Moreover, the elevated cash conversion cycle indicates potential inefficiencies in inventory management that could affect liquidity. On a positive note, the low debt levels and growing reserves position the company favorably to navigate market uncertainties. In scenarios where operational efficiencies are enhanced and margins improved, Adeshwar could see significant growth; conversely, continued margin compression and stagnant sales could lead to further investor skepticism and valuation pressures.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Constronics Infra Ltd | 71.9 Cr. | 57.4 | 108/46.0 | 16.3 | 32.8 | 0.00 % | 19.7 % | 15.8 % | 10.0 |
| Centenial Surgical Suture Ltd | 32.4 Cr. | 88.8 | 189/82.2 | 84.1 | 0.00 % | 3.94 % | 4.64 % | 10.0 | |
| Adeshwar Meditex Ltd | 30.3 Cr. | 21.0 | 21.8/13.3 | 14.6 | 26.1 | 0.00 % | 8.27 % | 5.51 % | 10.0 |
| Poly Medicure Ltd | 14,830 Cr. | 1,462 | 2,938/1,370 | 42.1 | 288 | 0.24 % | 20.1 % | 15.8 % | 5.00 |
| Mohini Health & Hygiene Ltd | 74.2 Cr. | 40.7 | 68.9/35.2 | 22.2 | 55.7 | 0.00 % | 14.1 % | 10.0 % | 10.0 |
| Industry Average | 14,830.00 Cr | 333.98 | 23.80 | 97.34 | 0.05% | 13.22% | 10.35% | 9.00 |
Quarterly Result
| Metric | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 36.53 | 29.45 | 30.21 | 34.54 | 46.06 | 36.30 | 46.26 | 33.59 | 40.90 | 37.45 | 30.06 |
| Expenses | 34.90 | 26.47 | 28.12 | 33.25 | 43.33 | 33.84 | 44.05 | 30.61 | 38.90 | 35.27 | 28.52 |
| Operating Profit | 1.63 | 2.98 | 2.09 | 1.29 | 2.73 | 2.46 | 2.21 | 2.98 | 2.00 | 2.18 | 1.54 |
| OPM % | 4.46% | 10.12% | 6.92% | 3.73% | 5.93% | 6.78% | 4.78% | 8.87% | 4.89% | 5.82% | 5.12% |
| Other Income | 0.09 | 0.17 | 0.02 | 0.21 | 0.08 | 0.22 | 0.08 | 0.05 | 0.21 | 0.17 | 0.05 |
| Interest | 1.08 | 1.11 | 1.02 | 1.01 | 1.04 | 1.01 | 1.03 | 0.90 | 0.71 | 0.31 | 0.36 |
| Depreciation | 0.17 | 0.17 | 0.17 | 0.22 | 0.26 | 0.27 | 0.29 | 0.31 | 0.25 | 0.21 | 0.21 |
| Profit before tax | 0.47 | 1.87 | 0.92 | 0.27 | 1.51 | 1.40 | 0.97 | 1.82 | 1.25 | 1.83 | 1.02 |
| Tax % | 29.79% | 27.27% | 26.09% | 59.26% | 27.81% | 29.29% | 25.77% | 29.12% | 28.00% | 27.32% | 28.43% |
| Net Profit | 0.33 | 1.36 | 0.68 | 0.11 | 1.09 | 0.99 | 0.73 | 1.28 | 0.90 | 1.34 | 0.73 |
| EPS in Rs | 0.63 | 1.29 | 0.47 | 0.08 | 0.76 | 0.69 | 0.51 | 0.89 | 0.62 | 0.93 | 0.51 |
Last Updated: December 28, 2025, 9:01 am
Below is a detailed analysis of the quarterly data for Adeshwar Meditex Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 30.06 Cr.. The value appears to be declining and may need further review. It has decreased from 37.45 Cr. (Mar 2025) to 30.06 Cr., marking a decrease of 7.39 Cr..
- For Expenses, as of Sep 2025, the value is 28.52 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 35.27 Cr. (Mar 2025) to 28.52 Cr., marking a decrease of 6.75 Cr..
- For Operating Profit, as of Sep 2025, the value is 1.54 Cr.. The value appears to be declining and may need further review. It has decreased from 2.18 Cr. (Mar 2025) to 1.54 Cr., marking a decrease of 0.64 Cr..
- For OPM %, as of Sep 2025, the value is 5.12%. The value appears to be declining and may need further review. It has decreased from 5.82% (Mar 2025) to 5.12%, marking a decrease of 0.70%.
- For Other Income, as of Sep 2025, the value is 0.05 Cr.. The value appears to be declining and may need further review. It has decreased from 0.17 Cr. (Mar 2025) to 0.05 Cr., marking a decrease of 0.12 Cr..
- For Interest, as of Sep 2025, the value is 0.36 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.31 Cr. (Mar 2025) to 0.36 Cr., marking an increase of 0.05 Cr..
- For Depreciation, as of Sep 2025, the value is 0.21 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.21 Cr..
- For Profit before tax, as of Sep 2025, the value is 1.02 Cr.. The value appears to be declining and may need further review. It has decreased from 1.83 Cr. (Mar 2025) to 1.02 Cr., marking a decrease of 0.81 Cr..
- For Tax %, as of Sep 2025, the value is 28.43%. The value appears to be increasing, which may not be favorable. It has increased from 27.32% (Mar 2025) to 28.43%, marking an increase of 1.11%.
- For Net Profit, as of Sep 2025, the value is 0.73 Cr.. The value appears to be declining and may need further review. It has decreased from 1.34 Cr. (Mar 2025) to 0.73 Cr., marking a decrease of 0.61 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.51. The value appears to be declining and may need further review. It has decreased from 0.93 (Mar 2025) to 0.51, marking a decrease of 0.42.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:19 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 58.60 | 52.92 | 56.12 | 65.97 | 64.76 | 82.36 | 79.85 | 83.71 | 67.51 |
| Expenses | 52.96 | 47.44 | 50.64 | 61.22 | 61.39 | 77.14 | 74.66 | 79.29 | 63.79 |
| Operating Profit | 5.64 | 5.48 | 5.48 | 4.75 | 3.37 | 5.22 | 5.19 | 4.42 | 3.72 |
| OPM % | 9.62% | 10.36% | 9.76% | 7.20% | 5.20% | 6.34% | 6.50% | 5.28% | 5.51% |
| Other Income | 0.10 | 0.25 | 0.28 | 0.13 | 0.23 | 0.31 | 0.13 | 0.26 | 0.22 |
| Interest | 1.78 | 2.23 | 2.52 | 2.19 | 2.03 | 2.09 | 1.93 | 1.39 | 0.67 |
| Depreciation | 0.36 | 0.35 | 0.34 | 0.35 | 0.38 | 0.53 | 0.60 | 0.50 | 0.42 |
| Profit before tax | 3.60 | 3.15 | 2.90 | 2.34 | 1.19 | 2.91 | 2.79 | 2.79 | 2.85 |
| Tax % | 29.72% | 28.25% | 27.24% | 28.63% | 33.61% | 28.52% | 27.96% | 26.16% | |
| Net Profit | 2.54 | 2.26 | 2.12 | 1.68 | 0.79 | 2.07 | 2.01 | 2.07 | 2.07 |
| EPS in Rs | 5.10 | 4.54 | 4.03 | 1.60 | 0.55 | 1.43 | 1.39 | 1.43 | 1.44 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -11.02% | -6.19% | -20.75% | -52.98% | 162.03% | -2.90% | 2.99% |
| Change in YoY Net Profit Growth (%) | 0.00% | 4.83% | -14.56% | -32.22% | 215.00% | -164.92% | 5.88% |
Adeshwar Meditex Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 9% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | 36% |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -10% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 6% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 2:06 pm
Balance Sheet
Last Updated: December 10, 2025, 3:44 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.98 | 4.98 | 5.27 | 10.53 | 14.43 | 14.43 | 14.43 | 14.43 | 14.43 |
| Reserves | 8.55 | 10.81 | 13.64 | 10.05 | 16.52 | 18.48 | 20.48 | 22.53 | 23.26 |
| Borrowings | 11.58 | 19.92 | 21.32 | 22.45 | 18.99 | 16.43 | 13.89 | 12.45 | 6.10 |
| Other Liabilities | 7.33 | 5.79 | 14.57 | 19.27 | 22.63 | 17.67 | 15.23 | 22.79 | 18.91 |
| Total Liabilities | 32.44 | 41.50 | 54.80 | 62.30 | 72.57 | 67.01 | 64.03 | 72.20 | 62.70 |
| Fixed Assets | 2.36 | 2.44 | 2.28 | 2.24 | 3.03 | 3.70 | 3.53 | 2.95 | 2.81 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.02 | 0.04 | 0.08 | 0.08 | 0.10 | 0.10 | 0.10 | 0.00 | 0.00 |
| Other Assets | 30.06 | 39.02 | 52.44 | 59.98 | 69.44 | 63.21 | 60.40 | 69.25 | 59.89 |
| Total Assets | 32.44 | 41.50 | 54.80 | 62.30 | 72.57 | 67.01 | 64.03 | 72.20 | 62.70 |
Below is a detailed analysis of the balance sheet data for Adeshwar Meditex Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 14.43 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.43 Cr..
- For Reserves, as of Sep 2025, the value is 23.26 Cr.. The value appears strong and on an upward trend. It has increased from 22.53 Cr. (Mar 2025) to 23.26 Cr., marking an increase of 0.73 Cr..
- For Borrowings, as of Sep 2025, the value is 6.10 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 12.45 Cr. (Mar 2025) to 6.10 Cr., marking a decrease of 6.35 Cr..
- For Other Liabilities, as of Sep 2025, the value is 18.91 Cr.. The value appears to be improving (decreasing). It has decreased from 22.79 Cr. (Mar 2025) to 18.91 Cr., marking a decrease of 3.88 Cr..
- For Total Liabilities, as of Sep 2025, the value is 62.70 Cr.. The value appears to be improving (decreasing). It has decreased from 72.20 Cr. (Mar 2025) to 62.70 Cr., marking a decrease of 9.50 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2.81 Cr.. The value appears to be declining and may need further review. It has decreased from 2.95 Cr. (Mar 2025) to 2.81 Cr., marking a decrease of 0.14 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 59.89 Cr.. The value appears to be declining and may need further review. It has decreased from 69.25 Cr. (Mar 2025) to 59.89 Cr., marking a decrease of 9.36 Cr..
- For Total Assets, as of Sep 2025, the value is 62.70 Cr.. The value appears to be declining and may need further review. It has decreased from 72.20 Cr. (Mar 2025) to 62.70 Cr., marking a decrease of 9.50 Cr..
Notably, the Reserves (23.26 Cr.) exceed the Borrowings (6.10 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.94 | -14.44 | -15.84 | -17.70 | -15.62 | -11.21 | -8.70 | -8.03 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 108.69 | 134.63 | 181.26 | 150.82 | 183.06 | 123.78 | 115.51 | 152.52 |
| Inventory Days | 64.44 | 112.51 | 119.36 | 174.35 | 168.24 | 127.72 | 138.71 | 126.64 |
| Days Payable | 43.11 | 38.76 | 104.70 | 119.86 | 138.51 | 88.18 | 75.97 | 104.03 |
| Cash Conversion Cycle | 130.02 | 208.39 | 195.93 | 205.31 | 212.79 | 163.33 | 178.25 | 175.13 |
| Working Capital Days | 129.43 | 108.29 | 124.03 | 111.49 | 147.05 | 116.60 | 129.04 | 135.78 |
| ROCE % | 17.69% | 14.27% | 11.22% | 6.93% | 10.07% | 9.62% | 8.27% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.43 | 1.39 | 1.44 | 0.55 | 1.59 |
| Diluted EPS (Rs.) | 1.43 | 1.39 | 1.44 | 0.59 | 1.59 |
| Cash EPS (Rs.) | 1.78 | 1.81 | 1.80 | 0.81 | 1.92 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 25.61 | 24.19 | 22.81 | 21.45 | 19.54 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 25.61 | 24.19 | 22.81 | 21.45 | 19.54 |
| Revenue From Operations / Share (Rs.) | 58.01 | 55.33 | 57.07 | 44.87 | 62.64 |
| PBDIT / Share (Rs.) | 3.21 | 3.68 | 3.80 | 2.49 | 4.76 |
| PBIT / Share (Rs.) | 2.86 | 3.26 | 3.43 | 2.23 | 4.43 |
| PBT / Share (Rs.) | 1.94 | 1.93 | 2.01 | 0.82 | 2.36 |
| Net Profit / Share (Rs.) | 1.43 | 1.39 | 1.44 | 0.54 | 1.59 |
| PBDIT Margin (%) | 5.52 | 6.64 | 6.66 | 5.55 | 7.60 |
| PBIT Margin (%) | 4.93 | 5.89 | 6.01 | 4.96 | 7.08 |
| PBT Margin (%) | 3.33 | 3.48 | 3.52 | 1.83 | 3.76 |
| Net Profit Margin (%) | 2.46 | 2.51 | 2.51 | 1.22 | 2.54 |
| Return on Networth / Equity (%) | 5.58 | 5.75 | 6.30 | 2.56 | 8.14 |
| Return on Capital Employeed (%) | 10.49 | 12.96 | 13.89 | 9.06 | 17.68 |
| Return On Assets (%) | 2.86 | 3.13 | 3.09 | 1.09 | 2.69 |
| Long Term Debt / Equity (X) | 0.05 | 0.03 | 0.07 | 0.13 | 0.25 |
| Total Debt / Equity (X) | 0.33 | 0.39 | 0.44 | 0.55 | 0.98 |
| Asset Turnover Ratio (%) | 1.23 | 1.22 | 1.18 | 0.96 | 1.13 |
| Current Ratio (X) | 2.03 | 2.06 | 1.90 | 1.76 | 1.59 |
| Quick Ratio (X) | 1.25 | 1.10 | 1.12 | 1.07 | 0.86 |
| Inventory Turnover Ratio (X) | 3.20 | 2.86 | 2.81 | 2.21 | 3.22 |
| Interest Coverage Ratio (X) | 3.47 | 2.76 | 2.68 | 1.78 | 2.29 |
| Interest Coverage Ratio (Post Tax) (X) | 2.55 | 2.04 | 2.01 | 1.39 | 1.83 |
| Enterprise Value (Cr.) | 33.89 | 60.21 | 36.79 | 54.94 | 0.00 |
| EV / Net Operating Revenue (X) | 0.40 | 0.75 | 0.44 | 0.84 | 0.00 |
| EV / EBITDA (X) | 7.33 | 11.34 | 6.71 | 15.26 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.28 | 0.59 | 0.29 | 0.61 | 0.00 |
| Price / BV (X) | 0.65 | 1.36 | 0.73 | 1.28 | 0.00 |
| Price / Net Operating Revenue (X) | 0.28 | 0.59 | 0.29 | 0.61 | 0.00 |
| EarningsYield | 0.08 | 0.04 | 0.08 | 0.02 | 0.00 |
After reviewing the key financial ratios for Adeshwar Meditex Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 5. It has increased from 1.39 (Mar 24) to 1.43, marking an increase of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 5. It has increased from 1.39 (Mar 24) to 1.43, marking an increase of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.78. This value is below the healthy minimum of 3. It has decreased from 1.81 (Mar 24) to 1.78, marking a decrease of 0.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.61. It has increased from 24.19 (Mar 24) to 25.61, marking an increase of 1.42.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.61. It has increased from 24.19 (Mar 24) to 25.61, marking an increase of 1.42.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 58.01. It has increased from 55.33 (Mar 24) to 58.01, marking an increase of 2.68.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.21. This value is within the healthy range. It has decreased from 3.68 (Mar 24) to 3.21, marking a decrease of 0.47.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.86. This value is within the healthy range. It has decreased from 3.26 (Mar 24) to 2.86, marking a decrease of 0.40.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.94. This value is within the healthy range. It has increased from 1.93 (Mar 24) to 1.94, marking an increase of 0.01.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 2. It has increased from 1.39 (Mar 24) to 1.43, marking an increase of 0.04.
- For PBDIT Margin (%), as of Mar 25, the value is 5.52. This value is below the healthy minimum of 10. It has decreased from 6.64 (Mar 24) to 5.52, marking a decrease of 1.12.
- For PBIT Margin (%), as of Mar 25, the value is 4.93. This value is below the healthy minimum of 10. It has decreased from 5.89 (Mar 24) to 4.93, marking a decrease of 0.96.
- For PBT Margin (%), as of Mar 25, the value is 3.33. This value is below the healthy minimum of 10. It has decreased from 3.48 (Mar 24) to 3.33, marking a decrease of 0.15.
- For Net Profit Margin (%), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 5. It has decreased from 2.51 (Mar 24) to 2.46, marking a decrease of 0.05.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.58. This value is below the healthy minimum of 15. It has decreased from 5.75 (Mar 24) to 5.58, marking a decrease of 0.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.49. This value is within the healthy range. It has decreased from 12.96 (Mar 24) to 10.49, marking a decrease of 2.47.
- For Return On Assets (%), as of Mar 25, the value is 2.86. This value is below the healthy minimum of 5. It has decreased from 3.13 (Mar 24) to 2.86, marking a decrease of 0.27.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 24) to 0.05, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.33. This value is within the healthy range. It has decreased from 0.39 (Mar 24) to 0.33, marking a decrease of 0.06.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.23. It has increased from 1.22 (Mar 24) to 1.23, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 2.03. This value is within the healthy range. It has decreased from 2.06 (Mar 24) to 2.03, marking a decrease of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 1.25. This value is within the healthy range. It has increased from 1.10 (Mar 24) to 1.25, marking an increase of 0.15.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.20. This value is below the healthy minimum of 4. It has increased from 2.86 (Mar 24) to 3.20, marking an increase of 0.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.47. This value is within the healthy range. It has increased from 2.76 (Mar 24) to 3.47, marking an increase of 0.71.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.55. This value is below the healthy minimum of 3. It has increased from 2.04 (Mar 24) to 2.55, marking an increase of 0.51.
- For Enterprise Value (Cr.), as of Mar 25, the value is 33.89. It has decreased from 60.21 (Mar 24) to 33.89, marking a decrease of 26.32.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.40, marking a decrease of 0.35.
- For EV / EBITDA (X), as of Mar 25, the value is 7.33. This value is within the healthy range. It has decreased from 11.34 (Mar 24) to 7.33, marking a decrease of 4.01.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 24) to 0.28, marking a decrease of 0.31.
- For Price / BV (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 1. It has decreased from 1.36 (Mar 24) to 0.65, marking a decrease of 0.71.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 24) to 0.28, marking a decrease of 0.31.
- For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.08, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Adeshwar Meditex Ltd:
- Net Profit Margin: 2.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.49% (Industry Average ROCE: 13.22%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.58% (Industry Average ROE: 10.35%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.55
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.25
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 14.6 (Industry average Stock P/E: 23.8)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.33
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.46%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | Gala 111 Lok Centre, MarolMaroshi Road, Mumbai Maharashtra 400059 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Abhinandan Nagaraja Rao | Chairman & Wholetime Director |
| Ms. Ashalata Baburao Raut | Managing Director |
| Mr. Krishnojirao Nagaraja Rao | Whole Time Director |
| Mr. Shailesh Vinayak Rajpure | Executive Director |
| Mr. Benegal Parameshwara Udpa | Ind. Non-Executive Director |
| Mr. Arun Koli | Ind. Non-Executive Director |
| Mr. Prithvi Sanjay Singh | Non Executive Director |
FAQ
What is the intrinsic value of Adeshwar Meditex Ltd?
Adeshwar Meditex Ltd's intrinsic value (as of 09 February 2026) is ₹20.77 which is 1.10% lower the current market price of ₹21.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹30.3 Cr. market cap, FY2025-2026 high/low of ₹21.8/13.3, reserves of ₹23.26 Cr, and liabilities of ₹62.70 Cr.
What is the Market Cap of Adeshwar Meditex Ltd?
The Market Cap of Adeshwar Meditex Ltd is 30.3 Cr..
What is the current Stock Price of Adeshwar Meditex Ltd as on 09 February 2026?
The current stock price of Adeshwar Meditex Ltd as on 09 February 2026 is ₹21.0.
What is the High / Low of Adeshwar Meditex Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Adeshwar Meditex Ltd stocks is ₹21.8/13.3.
What is the Stock P/E of Adeshwar Meditex Ltd?
The Stock P/E of Adeshwar Meditex Ltd is 14.6.
What is the Book Value of Adeshwar Meditex Ltd?
The Book Value of Adeshwar Meditex Ltd is 26.1.
What is the Dividend Yield of Adeshwar Meditex Ltd?
The Dividend Yield of Adeshwar Meditex Ltd is 0.00 %.
What is the ROCE of Adeshwar Meditex Ltd?
The ROCE of Adeshwar Meditex Ltd is 8.27 %.
What is the ROE of Adeshwar Meditex Ltd?
The ROE of Adeshwar Meditex Ltd is 5.51 %.
What is the Face Value of Adeshwar Meditex Ltd?
The Face Value of Adeshwar Meditex Ltd is 10.0.